GlaxoSmithKline PLC at JPMorgan Healthcare Conference (Virtual) Transcript
Good morning, and good afternoon. I'm James Gordon, JPMorgan European Pharma and Biotech analyst. And today at the JPMorgan conference, I've got the pleasure of introducing the GSK presentation and Q&A. So we have GSK CEO, Emma Walmsley, joining us for 20 minutes, and then we're going to have a 20-minute Q&A afterwards. And so with that said, thanks a lot for joining us today, Emma. Over to you for the presentation.
Thank you. Good morning, and good afternoon to everyone. A big thank you to James and a very happy new year to all of those attending today's virtual conference. Let me first refer you to our usual cautionary statement on Slide 2.
And then please turn to Slide 3. 2022 will be a landmark year for GSK. The demerger of our world-leading Consumer Healthcare business is set to unlock tremendous value for 2 new businesses set up for independent delivery of competitive growth, shareholder value and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
